
A New Chlamydia Vaccine on the Horizon
A first-in-human, Phase I clinical trial was successfully completed for a chlamydia vaccine, which is based on a recombinant protein…
ByA first-in-human, Phase I clinical trial was successfully completed for a chlamydia vaccine, which is based on a recombinant protein…
ByThe orphan drug market can be an alluringly lucrative sector. Most big pharma corporations inherit these specialty business units through mergers…
ByIn this issue: the disappearing supply of pink Migraleve in the UK, drug ingredients sourced from corn, using machine learning…
ByIn this issue: Knock on effects of the Valsartan recall, the future of AI in healthcare, the history of the…
ByIn this issue: A new class of cancer combo treatments, antidepressants in the environment, microbiome-based drug development, and more.
ByIn this issue: China’s growing pharmaceutical market, antimicrobial resistance, the rise of tech giants in healthcare, and more.
ByIn this issue: HPV vaccine programmes, dominantly inherited Alzheimer’s disease, a unique brain ‘fingerprint’ and more
ByIn this issue: Manufacturing personalised medicine, the economics of CAR-T treatments, AI in drug combination therapy and more.
ByThank you for subscribing to Pharmaceutical Technology